Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo.
The biosynthesis of the endocannabinoid anandamide (AEA) and related N-acyl ethanolamine (NAE) lipids is complex and appears to involve multiple pathways, including: (1) direct release of NAEs from N-acyl phosphatidyl ethanolamine (NAPE) precursors by the phosphodiesterase NAPE-PLD, and (2) double O-deacylation of NAPEs followed by phosphodiester bond hydrolysis of the resulting glycero-phospho (GP)-NAEs. We recently identified GDE1 as a GP-NAE phosphodiesterase that may be involved in the second pathway. Here, we report the generation and characterization of GDE1(-/-) mice, which are viable and overtly normal in their cage behavior. Brain homogenates from GDE1(-/-) mice exhibit a near-complete loss of detectable GP-NAE phosphodiesterase activity; however, bulk brain levels of AEA and other NAEs were unaltered in these animals. To address the possibility of compensatory pathways, we generated GDE1(-/-)/NAPE-PLD(-/-) mice. Conversion of NAPE to NAE was virtually undetectable in brain homogenates from these animals as measured under standard assay conditions, but again, bulk changes in brain NAEs were not observed. Interestingly, significant reductions in the accumulation of brain NAEs, including anandamide, were detected in GDE1(-/-)/NAPE-PLD(-/-) mice treated with a fatty acid amide hydrolase (FAAH) inhibitor that blocks NAE degradation. Finally, we determined that primary neurons from GDE1(-/-)/NAPE-PLD(-/-) mice can convert NAPEs to NAEs by a pathway that is not preserved following cell homogenization. In summary, combined inactivation of GDE1 and NAPE-PLD results in partial disruption of NAE biosynthesis, while also pointing to the existence of an additional enzymatic pathway(s) that converts NAPEs to NAEs. Characterization of this pathway should provide clarity on the multifaceted nature of NAE biosynthesis.
Simon
Gabriel M
GM
The Department of Chemical Physiology and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Cravatt
Benjamin F
BF
D000818:Animals; D000831:Animals, Newborn; D063385:Cannabinoid Receptor Modulators / Q000096:biosynthesis*; D063388:Endocannabinoids; D004983:Ethanolamines / Q000378:metabolism*; D005260:Female; D050356:Lipid Metabolism / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008954:Models, Biological; D009474:Neurons / Q000201:enzymology / Q000378:metabolism; D010739:Phospholipase D / Q000235:genetics* / Q000378:metabolism; D010727:Phosphoric Diester Hydrolases / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction / Q000235:genetics
D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D004983:Ethanolamines; D010739:Phospholipase D; D010727:Phosphoric Diester Hydrolases; C022203:N-acylethanolamines; C506062:Napepld protein, mouse; C038133:glycerophosphodiester phosphodiesterase
J Biol Chem. 2006 Sep 8;281(36):26465-72
16818490
J Pharmacol Exp Ther. 2005 Apr;313(1):352-8
15579492
J Biol Chem. 1989 May 25;264(15):8847-56
2722803
J Lipid Res. 2010 Jan;51(1):112-9
19584404
Bioorg Med Chem Lett. 2009 May 15;19(10):2865-9
19386497
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3999-4004
10760272
Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7656-60
8395053
Pharmacol Rev. 2006 Sep;58(3):389-462
16968947
Chem Phys Lipids. 2000 Nov;108(1-2):71-87
11106783
Biochim Biophys Acta. 1992 Aug 14;1113(2):135-60
1510994
J Neurochem. 1984 Jun;42(6):1613-9
6726229
Rev Physiol Biochem Pharmacol. 2008;160:1-24
18481028
Br J Pharmacol. 2004 Mar;141(5):775-85
14757702
Biochem Biophys Res Commun. 1963 Jan 31;10:165-70
14022413
Life Sci. 2005 Aug 19;77(14):1584-604
15979096
Pharmacol Biochem Behav. 2005 Jun;81(2):248-62
15935456
Chem Biol. 2009 Apr 24;16(4):411-20
19389627
J Biol Chem. 2008 Apr 4;283(14):9341-9
18227059
J Neurosci Methods. 2007 Mar 30;161(1):75-87
17118459
J Biol Chem. 2004 Feb 13;279(7):5298-305
14634025
Science. 1992 Dec 18;258(5090):1946-9
1470919
Cell. 1993 Dec 17;75(6):1137-44
8261513
Science. 1991 Feb 15;251(4995):804-7
1846707
Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):201-10
12052036
Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13345-50
16938887
Eur J Biochem. 1996 Aug 15;240(1):53-62
8797835
Nature. 1994 Dec 15;372(6507):686-91
7990962
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1745-50
12576545
Neuropharmacology. 2008 Jan;54(1):1-7
17631919
Fundam Clin Pharmacol. 2006 Dec;20(6):549-62
17109648
J Neurochem. 1983 Nov;41(5):1303-12
6619867
Biochemistry. 2006 Apr 18;45(15):4720-6
16605240
Chem Rev. 2008 May;108(5):1687-707
18429637
J Biol Chem. 2006 May 5;281(18):12325-35
16527816
Biochem Biophys Res Commun. 1979 Sep 27;90(2):628-33
508325
Biochim Biophys Acta. 2001 May 31;1532(1-2):121-7
11420181
Biochem Pharmacol. 1993 Sep 1;46(5):791-6
8373432
J Neurosci. 1996 Jun 15;16(12):3934-42
8656287
Neuropharmacology. 2004;47 Suppl 1:345-58
15464149